RxDoctor Payments Data

Leslye Jones, DO

Family Medicine · Georgetown, KYNPI 1376049569

Payments from drug & device makers

$2,778in general payments, 2019–2025

Across 128 payments — averaging $21.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$377
  • Novo Nordisk$341
  • Grifols USA, LLC$264
  • AstraZeneca$252
  • GSK$246
  • Lilly USA, LLC$217
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$2,74599%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,778 in reported general payments places this provider in the 75th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$34,489
Medicare patients
122
Services billed
575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$71,084
VraylarCariprazine Hcl24$34,563
EliquisApixaban25$24,858
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,503
FarxigaDapagliflozin Propanediol20$13,927
JardianceEmpagliflozin12$12,928
ShingrixVaricella-Zoster Ge/As01b/Pf33$7,440
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$4,745
ArexvyRsvpref3 Antigen/As01e/Pf13$4,066
Albuterol Sulfate HfaAlbuterol Sulfate62$2,545
Novolog FlexpenInsulin Aspart12$2,439
Gabapentin139$1,708
Boostrix TdapDiphth,pertuss(Acell),tet Vac17$1,198
Levothyroxine Sodium115$1,196
Omeprazole117$1,043

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$341$71,08460 claims
AbbVieVraylar$377$34,56324 claims
GSKTrelegy Ellipta, Shingrix, Arexvy$246$27,00970 claims
PfizerEliquis$99$24,85825 claims
AstraZenecaFarxiga$252$13,92720 claims
Boehringer IngelheimJardiance$44$12,92812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Georgetown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →